Bogaerts, Pierre
Berhin, Catherine
Nizet, Henri
Glupczynski, Gerald
[UCL]
BACKGROUND: Because of the increasing resistance of Helicobacter pylori against metronidazole and clarithromycin, alternative regimens including newer fluoroquinolones have been developed. We aimed to assess the prevalence as well as the mechanisms of this resistance in clinical isolates originating from patients living in Belgium. METHODS: Minimal inhibitory concentration (MIC) values of ciprofloxacin, levofloxacin, and moxifloxacin were determined by Etest method on 488 H. pylori isolates originating from patients who underwent upper gastrointestinal endoscopy at 10 different centers. Resistant strains (MIC values > 1 microg/ml) were evaluated for the presence of point mutations in the quinolone resistance-determining region (QRDR) of the gyrA by amplification and nucleotide sequence. RESULTS: Eighty-two (16.8%) of the strains were found resistant to all fluoroquinolones and 70 of these were further analyzed. Homogeneous and heterogeneous resistance were observed in 55 (78.6%) and in 15 (21.4%) of the strains, respectively. QRDR sequencing revealed various mutations of the codons corresponding to Asn-87 and Asp-91 in all isolates with homogeneous resistance. However, in 12 of 15 strains displaying heterogenous resistance, mutations were only detected after subcultures of isolated colonies growing within the ellipse inhibition zone of the E-test. Amino acid substitutions in the QRDR of GyrA could not be directly related with the MIC values of the isolates. Fluoroquinolone-resistant mutants were easily selected in vitro at frequencies ranging between 10(-6) and 10(-7). Such selected mutants stably persisted after several serial passage in antibiotic-free agar. CONCLUSIONS: These results suggest that H. pylori resistance to fluoroquinolones is occurring at a high frequency in the Belgian population and that it is essentially mediated through a variety of point mutations occurring in a few loci of GyrA. As a consequence, we strongly suggest to determine the susceptibility of the infecting isolates to fluoroquinolones before administration of an anti-H. pylori regimen including these agents.
- Malfertheiner P., Megraud F., O'Morain C., Hungin A. P. S., Jones R., Axon A., Graham D. Y., Tytgat G., , Current concepts in the management of Helicobacter pylori infection-The Maastricht 2-2000 Consensus Report, 10.1046/j.1365-2036.2002.01169.x
- Megraud F, H pylori antibiotic resistance: prevalence, importance, and advances in testing, 10.1136/gut.2003.022111
- Fischbach Lori A, Goodman Karen J, Feldman Mark, Aragaki Corinne, Sources of variation of Helicobacter pylori treatment success in adults worldwide: a meta-analysis, 10.1093/ije/31.1.128
- Fischbach L. A., Zanten S. V., Dickason J., Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies, 10.1111/j.1365-2036.2004.02248.x
- Lee J. H., Shin J.-H., Roe I. H., Sohn S. G., Lee J. H., Kang G. H., Lee H.-K., Jeong B. C., Lee S. H., Impact of Clarithromycin Resistance on Eradication of Helicobacter pylori in Infected Adults, 10.1128/aac.49.4.1600-1603.2005
- Antos David, Schneider-Brachert Wulf, Bastlein Elke, Hanel Christine, Haferland Christian, Buchner Michael, Meier Eberhard, Trump Friedrich, Stolte Manfred, Lehn Norbert, Bayerdorffer Ekkehard, 7-Day Triple Therapy of Helicobacter pylori Infection with Levofloxacin, Amoxicillin, and High-Dose Esomeprazole in Patients with Known Antimicrobial Sensitivity, 10.1111/j.0083-8703.2006.00375.x
- Gisbert Javier P., Castro-Fernandez Manuel, Bermejo Fernando, Perez-Aisa Angeles, Ducons Julio, Fernandez-Bermejo Miguel, Bory Felipe, Cosme Angel, Benito Luis-Miguel, Lopez-Rivas Laureano, Lamas Eloisa, Pabon Manuel, Olivares David, , Third-Line Rescue Therapy with Levofloxacin After Two H. pylori Treatment Failures, 10.1111/j.1572-0241.2006.00457.x
- GISBERT J. P., MORENA F., Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure, 10.1111/j.1365-2036.2006.02737.x
- WONG W. M., GU Q., CHU K.-M., YEE Y. K., FUNG F. M. Y., TONG T. S. M., CHAN A. O. O., LAI K. C., CHAN C. K., WONG B. C. Y., Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infection, 10.1111/j.1365-2036.2006.02764.x
- Debets-Ossenkopp Y. J., Herscheid A. J., Pot R. G. J., Kuipers E. J., Kusters J. G., Vandenbroucke-Grauls C. M. J. E., Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxycillin, tetracycline and trovafloxacin in The Netherlands, 10.1093/jac/43.4.511
- Cabrita J., Features and trends in Helicobacter pylori antibiotic resistance in Lisbon area, Portugal (1990-1999), 10.1093/jac/46.6.1029
- Boyanova L., Mentis A., Gubina M., Rozynek E., Gosciniak G., Kalenic S., Göral V., Kupcinskas L., Kantarçeken B., Aydin A., Archimandritis A., Dzierżanowska D., Vcev A., Ivanova K., Marina M., Mitov I., Petrov P., Özden A., Popova M., The status of antimicrobial resistance of Helicobacter pylori in eastern Europe, 10.1046/j.1469-0691.2002.00435.x
- Tankovic J., Lascols C., Sculo Q., Petit J.-C., Soussy C.-J., Single and Double Mutations in gyrA but Not in gyrB Are Associated with Low- and High-Level Fluoroquinolone Resistance in Helicobacter pylori, 10.1128/aac.47.12.3942-3944.2003
- Fujimura S., In vitro activity of fluoroquinolone and the gyrA gene mutation in Helicobacter pylori strains isolated from children, 10.1099/jmm.0.45642-0
- Cattoir V, Helicobacter, 10, 542 (2005)
- Kim Jung Mogg, Kim Joo Sung, Kim Nayoung, Jung Hyun Chae, Song In Sung, Distribution of fluoroquinolone MICs in Helicobacter pylori strains from Korean patients, 10.1093/jac/dki334
- Perez Aldana L., Kato M., Nakagawa S., Kawarasaki M., Nagasako T., Mizushima T., Oda H., Kodaira J., Shimizu Y., Komatsu Y., Zheng R., Takeda H., Sugiyama T., Asaka M., The Relationship Between Consumption of Antimicrobial Agents and the Prevalence of Primary Helicobacter pylori Resistance, 10.1046/j.1523-5378.2002.00096.x
- 18 H Goossens, M Ferech, R Vander Stichele, M. Elseviers, and ESAC Project Group. and Outpatient antibiotic use in Europe and association with resistance: a cross-national database study . Lancet, 2005 : 365 (9459, 579-87.
- Moore R. A., Beckthold B., Wong S., Kureishi A., Bryan L. E., Nucleotide sequence of the gyrA gene and characterization of ciprofloxacin-resistant mutants of Helicobacter pylori, 10.1128/aac.39.1.107
- Glocker E., Kist M., Rapid Detection of Point Mutations in the gyrA Gene of Helicobacter pylori Conferring Resistance to Ciprofloxacin by a Fluorescence Resonance Energy Transfer-Based Real-Time PCR Approach, 10.1128/jcm.42.5.2241-2246.2004
- Haas C E, Nix D E, Schentag J J, In vitro selection of resistant Helicobacter pylori., 10.1128/aac.34.9.1637
- Wang G., Wilson T. J. M., Jiang Q., Taylor D. E., Spontaneous Mutations That Confer Antibiotic Resistance in Helicobacter pylori, 10.1128/aac.45.3.727-733.2001
- Y. Glupczynski, N. Broutet, A. Cantagrel, L. Andersen, T. Alarcon, M. López-Brea, F. Mégraud, Comparison of the E Test and Agar Dilution Method for Antimicrobial Suceptibility Testing of Helicobacter pylori, 10.1007/s10096-002-0757-6
Bibliographic reference |
Bogaerts, Pierre ; Berhin, Catherine ; Nizet, Henri ; Glupczynski, Gerald. Prevalence and mechanisms of resistance to fluoroquinolones in Helicobacter pylori strains from patients living in Belgium.. In: Helicobacter, Vol. 11, no. 5, p. 441-5 (2006) |
Permanent URL |
http://hdl.handle.net/2078.1/10701 |